Your AI-Trained Oncology Knowledge Connection!

Isaac Raijman, MD

Articles

Phase I Study of Irinotecan and Concurrent Radiation Therapy for Upper GI Tumors

Ritsuko Komaki, MD;Nora A. Janjan, MD;Jaffer A. Ajani, MD;Patrick M. Lynch, MD;Jackie S. Fairweather, RN;Isaac Raijman, MD;George R. Blumenshein, MD;Linus Ho, MD, PhD;Peter W. T. Pisters, MD;Barry W. Feig, MD;Garrett L. Walsh, MD;Richard Pazdur, MD

December 3rd 2000

Irinotecan (Camptosar) is an active chemotherapeutic agent for lung, gastric, esophageal, and colorectal cancers and a potent radiosensitizer. This phase I study was designed to assess the maximum tolerated dose of weekly

Commentary (Raijman/Wallace): Management of Malignant Biliary Obstruction: Nonoperative and Palliative Techniques

Isaac Raijman, MD;Sidney Wallace, MD

June 1st 1995

The first description of percutaneous biliary drainage in the United States appeared in 1965 [1]. The percutaneously placed catheters were left in the obstructed biliary tract for drainage for up to 5 days. Since then, biliary drainage techniques have advanced substantially, and options have proliferated. Now, the nonsurgical palliation of malignant biliary obstruction, accomplished either endoscopically or percutaneously, is a well-established therapeutic modality.